Imunexus platform adds a new twist to bispecific development
· tamra sami
AI Briefing
- • Imunexus Co. Ltd. develops a modular platform for bispecific biologics using imunexins and existing drugs.
- • Imunexins are small, engineered protein molecules that attach to drugs to create bi- and multispecific biologics.
- • The platform allows for the creation of new biologics by modifying existing drugs.
Context
Imunexus Co. Ltd. has developed a modular platform for creating bi- and multispecific biologics. The platform uses small, engineered protein molecules called imunexins. These imunexins are attached to existing drugs, including antibodies, enzymes, and other recombinant proteins.
The Imunexus platform offers a new approach to bispecific development. By using imunexins to create bi- and multispecific biologics, the company is expanding the possibilities for drug development.
Advertisement